Axogen has completed its $200 million cash acquisition of BioCircuit Technologies, adding NerveTape, an FDA-cleared sutureless device for repairing cut peripheral nerves, to its nerve repair portfolio. The company announced on 1 October 2026 that the Axogen BioCircuit acquisition had closed, three weeks after the definitive agreement was signed on 10 September. Here is what NerveTape does, how the deal is structured and what Axogen expects from it.
Key Takeaways
- Axogen paid $200 million in cash for BioCircuit Technologies, a privately held medical device company, and completed the deal on 1 October 2026.
- BioCircuit makes NerveTape, described as the first FDA-cleared sutureless device for repairing transected nerves.
- Axogen expects BioCircuit to contribute about $6 million to fourth-quarter 2026 revenue and about $34 million in 2027. These amounts are not included in its earlier 2026 guidance.
- Axogen says it still expects gross margin of at least 73% for 2026 and to be free cash positive for the full year.
- All figures are company-reported forward-looking statements and may change.
What Is the Deal?
Axogen, based in Alachua, Florida, agreed on 10 September 2026 to buy BioCircuit in an all-cash transaction, with closing expected in the fourth quarter and subject to customary conditions, including BioCircuit’s planned spin-out of an unrelated electronics business. The deal closed on 1 October. No additional financing details were disclosed in the announcements we reviewed. BioCircuit’s investors are named as Alsora Capital, GRA Venture Fund and Michael Masters of Masters Capital Management.
Axogen and BioCircuit Deal at a Glance
| Item | Detail |
|---|---|
| Acquirer | Axogen (Alachua, Florida) |
| Target | BioCircuit Technologies, privately held; maker of NerveTape |
| Price | $200 million, all cash |
| Agreement signed | 10 September 2026 |
| Completed | 1 October 2026 |
| Product | NerveTape, sutureless peripheral nerve repair device (FDA-cleared) |
| Expected BioCircuit revenue | About $6M in Q4 2026; about $34M in 2027 (company projection) |
| Guidance | Gross margin of at least 73% for 2026; free cash positive for the full year |
What Is NerveTape?
NerveTape is a sutureless nerve repair device. Rather than stitching the two ends of a cut nerve together under a microscope, a surgeon uses the device, which relies on miniature hooks, to bring the nerve ends together and hold them in alignment while the nerve heals. One report says it was the first sutureless peripheral nerve repair technology to receive FDA clearance, in July 2022. Clearance by the US Food and Drug Administration means the agency found the device to be substantially equivalent to a legally marketed device, which differs from a drug-style approval. Some reports use the word approved, and we use cleared because it is the term in the company’s announcement.
Axogen says NerveTape is simpler, faster and more effective than microsuturing, and its chief executive Michael Dale described it as a new standard of care in the company’s announcement. Those are the company’s claims, and we have not reviewed independent comparative data. The company also says the device reduces dependence on specialised microsurgical skill and can support wider adoption across care settings.
Why Does Axogen Want It?
Axogen’s existing products include the Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector and Avive+ Soft Tissue Matrix. The company says NerveTape fits its mission and can be sold through its existing direct sales force, hospital contracting relationships and surgeon networks. It also plans to explore new product opportunities and indications using BioCircuit’s technology platform. Chief Financial Officer Lindsey Hartley called it an attractive growth asset, according to one report.
By our own calculation, the $200 million price is about six times the roughly $34 million of 2027 revenue the company expects from BioCircuit. That is a simple ratio of the price to the company’s own projection, not a formal valuation, and it depends on the projection being met.
Why Peripheral Nerve Repair Matters
Peripheral nerves carry signals between the brain, spinal cord and the rest of the body, and injuries from trauma or surgery can cause loss of sensation or movement. General information on nerve disorders is published by the National Institute of Neurological Disorders and Stroke. Repair of a transected nerve has traditionally relied on fine sutures, which require specialised microsurgical skill and can be time-consuming. Devices that simplify the repair could widen the number of surgeons able to treat these injuries, although outcomes data will decide how far that happens.
What Is Not Yet Known
- Independent evidence comparing NerveTape with suture repair on functional recovery.
- How quickly Axogen can increase NerveTape sales beyond the company’s projections.
- Whether new indications or products from the BioCircuit platform will reach the market and when.
- Reimbursement and pricing for NerveTape across hospitals and regions.
Related Coverage
For more on surgical technology and the device market, see our reports on the AI-assisted surgery market outlook, the trade-margin talks for medical devices and hospital consumables and the parliamentary panel’s call for wider device price control.
Our Assessment
In our assessment, the deal is a logical bolt-on: it gives Axogen a differentiated, already-cleared product it can push through an established sales channel, and it is financed in cash from a company that says it will stay free cash positive. The risk is that adoption depends on surgeons being convinced that a sutureless repair is at least as good as the established approach. Investors and clinicians should watch outcomes data and revenue against the company’s projections.
Frequently Asked Questions
What did Axogen acquire?
Axogen acquired BioCircuit Technologies, the maker of NerveTape, a sutureless device for repairing transected peripheral nerves.
How much did the acquisition cost?
$200 million in cash. The deal was announced on 10 September 2026 and completed on 1 October 2026.
What is NerveTape?
A device that uses miniature hooks to bring cut nerve ends together without sutures. It is FDA-cleared, according to the companies.
How much revenue does Axogen expect from BioCircuit?
About $6 million in the fourth quarter of 2026 and about $34 million in 2027, according to the company. These are projections.
Does the deal change Axogen’s guidance?
The company says BioCircuit’s expected contribution is not included in its earlier 2026 guidance. It maintains its gross margin expectation of at least 73%.
How we reported this: details come from Axogen’s announcements of the agreement on 10 September 2026 and the completed deal on 1 October 2026. Figures and quotes are company-reported and forward-looking. We did not see independent clinical data. Last updated 5 October 2026. This article is for information only and is not medical or investment advice.